Vous êtes ici

2016

Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L, INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10023):1075-84. IF2015 = 44.002; 5YIF = 46.119

 

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Seze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. Neurology. 2016;86(8):771-8. IF2015 = 8.166; 5YIF = 8.092

 

Tenembaum S, Chitnis T, Nakashima I, Collongues N, McKeon A, Levy M, Rostasy K. Neuromyelitis optica spectrum disorders in children and adolescents. Neurology. 2016;1-8. IF2015 = 8.166; 5YIF = 8.092

 

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Seze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zephir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D. CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. Neurology. 2016; 87:2491-4. IF2015 = 8.166; 5YIF = 8.092

 

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators..Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology. 2016 Nov 8;87(19):1985-1992. IF2015 = 8.166; 5YIF = 8.092

 

Truchetet ME, Demoures B, Guimaraes JE, Bertrand A, Laurent P, Jolivel V, Douchet I, Jacquemin C, Khoryati L, Duffau P, Lazaro E, Richez C, Seneschal J, Doutre MS, Pellegrin JL, Constans J, Schaeverbeke T, Blanco P, Contin-Bordes C. Platelets Induce Thymic Stromal Lymphopoietin Production by Endothelial Cells: Contribution to Fibrosis in Human Systemic Sclerosis. Arthritis Rheumatol. 2016 Nov;68(11):2784-2794. IF2015 = 6.009;

5YIF = 6.050

 

Grimm A, Biliouris EE, Lang UE, Götz J, Mensah-Nyagan AG, Eckert A. Sex hormone-related neurosteroids differentially rescue bioenergetic deficits induced by amyloid-β or hyperphosphorylated tau protein. Cell Mol Life Sci. 2016;73(1):201-15. IF2015 = 5.694; 5YIF = 5.570

 

Duval CZ, Goumon Y, Kemmel V, Kornmeier J, Dufour A, Andlauer O, Vidailhet P, Poisbeau P, Salvat E, Muller A, Mensah-Nyagan AG, Schmidt-Mutter C, Giersch A. Neurophysiological responses to unpleasant stimuli (acute electrical stimulations and emotional pictures) are increased in patients with schizophrenia. Sci Rep. 2016;6:22542. IF2015 = 5.228; 5YIF = 5.525

 

Chan A, de Seze J, Comabella M. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis. CNS Drugs. 2016;30(1):41-51. IF2015 = 4.910; 5YIF = 4.692

 

Cohen M, De Seze J, Marignier R, Lebrun C. False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients. Mult Scler. 2016. pii: 1352458516630823. IF2015 = 4.671; 5YIF = 4.546

 

Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R, OFSEP and CFSEP. Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler. 2016;22(7):955-9. IF2015 = 4.671; 5YIF = 4.546

 

Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2016; pii: 1352458516678474. IF2015 = 4.671; 5YIF = 4.546

Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Seze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group.. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.Mult Scler. 2016 Nov;22(13):1719-1731. IF2015 = 4.671; 5YIF = 4.546

Ernst A, Noblet V, Denkova E, Blanc F, De Seze J, Gounot D, Manning L. Distinct and common cerebral activation changes during mental time travel in relapsing-remitting multiple sclerosis patients. Brain Imaging Behav. 2016;10(1):296-313.IF2015 = 3.667; 5YIF = 4.159

 

Morozova A, Zubkov E, Strekalova T, Kekelidze Z, Storozeva Z, Schroeter CA, Bazhenova N, Lesch KP, Cline BH, Chekhonin V. Ultrasound of alternating frequencies and variable emotional impact evokes depressive syndrome in mice and rats. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jul 4;68:52-63. IF2015 = 4.361; 5YIF = 4.111

 

Karout M, Miesch M, Geoffroy P, Kraft S, Hofmann HD, Mensah-Nyagan AG, Kirsch M. Novel analogs of allopregnanolone show improved efficiency and specificity in neuroprotection and stimulation of proliferation. J Neurochem. 2016;doi: 10.1111/jnc.13693. IF2015 = 3.842; 5YIF = 3.808

 

Juryńczyk M, Weinshenker B, Akman-Demir G, Asgari N, Barnes D, Boggild M, Chaudhuri A, D'hooghe M, Evangelou N, Geraldes R, Illes Z, Jacob A, Kim HJ, Kleiter I, Levy M, Marignier R, McGuigan C, Murray K, Nakashima I, Pandit L, Paul F, Pittock S, Selmaj K, de Seze J, Siva A, Tanasescu R, Vukusic S, Wingerchuk D, Wren D, Leite I, Palace J. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol. 2016;263(1):140-9. IF2015 = 3.408; 5YIF = 3.349

 

Roussel G, Bessede A, Klein C, Maitre M, Mensah-Nyagan AG. Xanthurenic acid is localized in neurons in the central nervous system. Neuroscience. 2016;329:226-38. IF2015 = 3.231; 5YIF = 3.204

 

Ernst A, Sourty M, Roquet D, Noblet V, Gounot D, Blanc F, De Seze J, Manning L. Functional and structural cerebral changes in key brain regions after a facilitation programme for episodic future thought in relapsing-remitting multiple sclerosis patients. Brain Cogn. 2016;105:34-45. IF2015 = 2.399; 5YIF = 3.019

 

Guffroy A, Dima A, Nespola B, Poindron V, Sibilia J, Herbrecht R, De Seze J, Habersetzer F, Andres E, Quoix E, Ohlmann P, Cribier B, Langer B, Martin T, Pasquali JL, Goetz J, Korganow AS. Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE. Joint Bone Spine. 2016;83(3):330-4. IF2015 = 2.946;

5YIF = 2.798

 

Pottecher J, Kindo M, Chamaraux-Tran TN, Charles AL, Lejay A, Kemmel V, Vogel T, Chakfe N, Zoll J, Diemunsch P, Geny B. Skeletal muscle ischemia-reperfusion injury and cyclosporine A in the aging rat. Fundam Clin Pharmacol. 2016;30(3):216-25. IF2015 = 2.156; 5YIF = 1.844

 

Berna F, Blanc F, Lebrun C, Castelnovo G, Clerc C, Debouverie M, Jouvenoz D, Marcel-Viallet M, Zaenker C, Zephir H, Vidailhet P, De Seze J. Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study. Mult Scler Relat Disord. 2016;6:93-6. IF2015 = 1.150; 5YIF = 1.201

 

Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. J Neurol Sci. 2016;363:69-76. IF2015 = 0.137; 5YIF = 0.139

de Seze J, Kremer L, Alves do Rego C, Taleb O, Lam D, Beiano W, Mensah-Nyagan G, Trifilieff E, Brun S. Chronic inflammatory demyelinating polyradiculoneuropathy: A new animal model for new therapeutic targets. Rev Neurol (Paris). 2016 Dec;172(12):767-769. IF2015 = 0.955; 5YIF = 0.711

Ernst A, Sourty M, Roquet D, Noblet V, Gounot D, Blanc F, de Seze J, Manning L. Benefits from an autobiographical memory facilitation programme in relapsing-remitting multiple sclerosis patients: a clinical and neuroimaging study.Neuropsychol Rehabil. 2016 Oct 9:1-21. IF2015 =2.082; 5YIF = 2.706

Voltzenlogel V, Ernst A, de Seze J, Brassat D, Manning L, Berna F. Giving meaning to illness: An investigation of self-defining memories in patients with relapsing-remitting multiple sclerosis patients. Conscious Cogn. 2016 Oct;45:200-209. IF2015 =2.182; 5YIF = 2.428.

Revues:

Grimm A, Mensah-Nyagan AG, Eckert A. Alzheimer, mitochondria and gender. Neurosci Biobehav Rev. 2016. pii: S0149-7634(15)30066-X. doi: 10.1016/j.neubiorev.2016.04.012. IF2015 = 8.580; 5YIF = 10.504

 

Maitre M, Klein C, Mensah-Nyagan AG. Mechanisms for the Specific Properties of γ-Hydroxybutyrate in Brain. Med Res Rev. 2016;36(3):363-88. IF2015 = 9.135; 5YIF = 8.648

Maitre M, Klein C, Mensah-Nyagan AG. A proposed preventive role for Gamma-hydroxybutyrate (XyremR) in Alzheimer’s disease. Alzheimer’s Research and Therapy. In revision. IF2015 = 5.197; 5YIF = 5.126

Chan A, de Seze J, Comabella M. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis. CNS Drugs. 2016;30(1):41-51. IF2015 = 4.910; 5YIF = 4.692

 

Collongues N, de Seze J. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord. 2016;9(3):180-8. IF2015 = 2.642

 

Collart Dutilleul P, Ryvlin P, Kahane P, Vercueil L, Semah F, Biraben A, Schwartz JC, De Seze J, Hirsch E, Collongues N. Exploratory Phase II Trial to Evaluate the Safety and the Antiepileptic Effect of Pitolisant (BF2.649) in Refractory Partial Seizures, Given as Adjunctive Treatment During 3 Months. Clin Neuropharmacol. 2016; DOI:10.1097/WNF.0000000000000159. IF2015 = 1.748; 5YIF = 1.932

 

de Seze J, Kremer L, Collongues N. Neuromyelitis optica spectrum disorder (NMOSD): A new concept. Rev Neurol (Paris). 2016;172(4-5):256-62. IF2015 = 0.955; 5YIF = 0.711